Riskpilot← Back to searchSign inGet full accessMedNOx AB
ABActiveOrg 5567942387Pålkällan 6Medical specialists activities · NACE 8622Est. 20091 employees
Revenue 2024
SEK 61K
-92% vs 2023
EBITDA margin
-160.7%
-117% vs 2023
Equity ratio
64.2%
Financial strength
Net profit 2024
SEK 32K
-79% vs 2023
| Revenue | SEK 61K | -92% |
| EBITDA | SEK -98K | -117% |
| Net profit | SEK 32K | -79% |
| Total assets | SEK 848K | -37% |
| Equity | SEK 544K | -24% |
| Employees | 1 | — |
Legal name
MedNOx AB
Org number
5567942387
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
23 november 2009
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva sjukvård, utbildning inom sjukvård och skärmflygning, mineralprospektering, handel med råvaror och värdepapper samt fastighetsförvaltning.
Address
Pålkällan 6
Email
annsberg.martin@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 605 | 1 144 | 121 | 789 | 61 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 480 | 970 | −125 | 572 | −98 |
| Depreciation & amort. | −3 | −56 | −72 | −10 | −28 |
| EBIT | 477 | 914 | −197 | 562 | −126 |
| Net financials | −208 | −465 | 51 | −330 | 11 |
| Profit before tax | 253 | 464 | 48 | 240 | 45 |
| Tax | −78 | −145 | −2 | −86 | −13 |
| Net profit | 175 | 319 | 46 | 154 | 32 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 324 | 1 785 | 938 | 1 336 | 848 |
| Equity | 893 | 712 | 558 | 712 | 544 |
| Long-term debt | 0 | 207 | 0 | 0 | 0 |
| Short-term debt | 165 | 389 | 96 | 180 | 20 |
| Total debt | 165 | 596 | 96 | 180 | 20 |
EBITDA margin
-160.7%
This company
15.8%
Market median
-1117% vs market
20202024
Equity ratio
64.2%
This company
38.2%
Market median
+68% vs market
20202024
Return on equity
5.9%
This company
18.4%
Market median
-68% vs market
20202024
Net profit margin
52.5%
This company
8.1%
Market median
+548% vs market
20202024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20202024
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MedNOx AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Magnus Skogs | Deputy Board Member | 0 companies |
| Arne Martin Annsberg | Board of Directors | 0 companies |